240 results about "Lipid accumulation" patented technology

The invention discloses a method for improving beef quality, an action mechanism and an experimental method, in a cattle body, vitamin A can activate the expression of EBF2 through an active metabolite RA of the vitamin A, and the EBF2 can inhibit the transcription process of CYP26B1 in a targeted manner to maintain the activity of a retinol signal channel, so that PPAR gamma and downstream lipid metabolism related genes thereof are activated, and the activity of the retinol signal channel is improved. Fatty acid transport and lipid accumulation in fat cells in the cattle muscle are promoted, fat deposition in the cattle muscle is promoted, and the beef quality is improved. By constructing the molecular network for regulating and controlling the formation of the fat in the cattle muscle, a complex regulation and control mechanism for controlling the fat deposition in the cattle muscle can be understood more deeply, a method for improving the beef quality based on regulating and controlling the vitamin A mediated key factor EBF2 is provided, and a new way is provided for improving the beef quality in a targeted manner.

The invention relates to gardenia polysaccharide as well as a preparation method and application thereof. The gardenia polysaccharide comprises the following monosaccharide units: rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, or mainly comprises rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose; the molar ratio of rhamnose to glucuronic acid to galacturonic acid to glucose to galactose to arabinose in the gardenia polysaccharide is (3-15): (1-8): (4-18): (1-6): (15-35): (25-70). According to the gardenia polysaccharide, FFA induced mouse primary parenchymal hepatic cell lipid accumulation can be reduced, no obvious cytotoxic effect exists, CDAHFD diet induced hepatic fibrosis can be reduced, and the gardenia polysaccharide has a good effect of preventing and / or treating non-alcoholic steatohepatitis.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention relates to the technical field of natural compounds, in particular to ganoderma leukemia polysaccharide and a preparation method thereof. The ganoderma leukemia polysaccharide comprises galactose, glucose and mannose, and the molar ratio of the galactose to the mannose to the glucose is (1.5-3.5): (15-30): (65-85); the ganoderma leukemia polysaccharide comprises:-> 6)-Glcp-(1-> dominant residues; (-> 6)-Manp-(1->,-> 4)-Glcp-(1-> residue; and-> 4, 6)-Manp-(1->,-> 3, 6)-Galp-(1->. The ganoderma leukemia polysaccharide has anti-oxidation and detoxification capabilities, can avoid neurodegenerative diseases, reduce lipid accumulation and prolong the service life, and also has high-temperature resistance.

The invention relates to the technical field of molecular biology, gene therapy and drug development, and provides application of TRIM44 as a target in preparation of a drug for treating non-alcoholic fatty liver. The medicine prevents, relieves and / or treats the non-alcoholic fatty liver disease by inhibiting the expression level of TRIM44. According to the application disclosed by the invention, the TRIM44 is taken as a target, and the non-alcoholic fatty liver is prevented, relieved and treated by reducing the expression level of the TRIM44. The TRIM44 inhibitor enables the liver weight and the proportion of the liver in the body weight of a patient to be remarkably reduced, lipid accumulation to be reduced, fat deposition and vacuolation degree of liver tissue to be reduced and liver texture to be improved under poor diet conditions of high fat, high sugar and the like, so that the non-alcoholic fatty liver is prevented, relieved and treated, and the health state of the patient is improved.

The invention belongs to the field of intestinal microbiology, and discloses a novel ackermania muciniphila capable of improving obesity and glycolipid metabolism, and the ackermania muciniphila strains are Akk-101 and AMY001. The preservation number of the Akk-101 is CGMCC (China General Microbiological Culture Collection Center) No. 40786, and the preservation number of the AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have acid-base tolerance and colonization ability superior to those of the standard strains, and have the effects of more effectively inhibiting lipid accumulation of liver cells, reducing fat deposition in nematode bodies, losing weight and improving glycolipid metabolism. Therefore, related products can be effectively developed based on the strain.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

The invention relates to application of 9-cis-retinoic acid in preparation of products for treating, preventing or improving obesity, and belongs to the technical field of biological medicine. Experimental evaluation of obese mice induced by high-fat diet proves that the 9-cis-retinoic acid can reduce blood fat and improve the glycometabolism function, and lipid accumulation of the liver is improved mainly by increasing expression of main regulatory protein PPAR-alpha oxidized by liver beta, so that the 9-cis-retinoic acid can be used for preparing medicines for treating obesity. The traditional Chinese medicine composition can be used for treating, preventing or improving metabolic symptoms caused by high fat diet, and a new strategy is provided for treating obesity and related metabolic syndromes. Besides, 9-cis-retinoic acid is a natural active metabolite of vitamin A, does not show obvious toxic reaction in animal experiments, and has better biocompatibility.

The invention belongs to the technical field of pharmacotherapeutics, and particularly relates to application of theaflavin-3 '-gallate and a medicine prepared from theaflavin-3'-gallate. The theaflavin-3 '-gallate is used as a KEAP1-NRF2 inhibitor and is competitively combined with the KEAP1 to destroy the inhibition effect of the KEAP1 on the NRF2, so that the content of the NRF2 is increased, and the expression of downstream NQO1 and GCLC is improved. Besides, the theaflavin-3 '-gallate protects the liver function by inhibiting the increase of the contents of AST and ALT, and reduces the oxidative stress and lipid accumulation of the liver, so that the theaflavin-3'-gallate has the potential to become a medicine for treating the ethanol-induced liver injury.

The invention relates to a novel spirobenzylisoquinoline alkaloid hypecoum erectum ketone base C extracted from hypecoum erectum as well as a preparation method and application of the novel spirobenzylisoquinoline alkaloid hypecoum erectum ketone base C, which can be used for effectively extracting and preparing the novel spirobenzylisoquinoline alkaloid hypecoum erectum ketone base C from the hypecoum erectum and realizing the application in preparing a medicine for preventing and treating a non-alcoholic fatty liver disease. Carrying out heating reflux extraction on the dried hypecoum erectum by using ethanol, carrying out acid extraction and alkali precipitation, and sequentially extracting by using chloroform and n-butyl alcohol to obtain an extract of a corresponding part; and mixing the target extract with silica gel, eluting, concentrating under reduced pressure, detecting, combining the same fractions, eluting on a column, mixing the silica gel with the sample, eluting, collecting the fractions with retention time, concentrating and drying to obtain the anise keto alkali C. The invention also discloses a preparation method of the anise keto alkali C. The invention also discloses a preparation method of the anise keto alkali C. The compound can significantly improve free fatty acid-induced HepG2 cell lipid metabolism disorder and lipid accumulation, meanwhile alleviate FFA-induced HepG2 cell damage, can be prepared into various drug dosage forms, is convenient and effective in clinical use, has wide development and application prospects, and has significant economic and social benefits.

The invention provides polygonatum kingianum polysaccharide and application thereof in a medicine for treating diabetes mellitus, the molecular weight of the polygonatum kingianum polysaccharide is 2365Da, and the polygonatum kingianum polysaccharide is uniform polysaccharide; the polygonatum kingianum polysaccharide is prepared from arabinose, fructose, galactose, glucose and ribose according to the mass ratio of 39.19: 24.28: 2.85: 1.37: 3.38, the polygonatum kingianum polysaccharide is simple in preparation method, low in cost and free of pollution, and the obtained polysaccharide is high in purity; an in-vitro lipid-lowering and blood-glucose-lowering activity experiment result of the polygonatum kingianum polysaccharide shows that the polygonatum kingianum polysaccharide can obviously reduce lipid accumulation of human liver cancer HepG2 cells and obviously improve glucose consumption of insulin-resistant cells, the polygonatum kingianum polysaccharide has good in-vitro lipid-lowering and blood-glucose-lowering activity, and a new way is provided for treating and preventing diabetes mellitus.

The invention discloses a preserving fluid for relieving ischemia-reperfusion injury of transplanted fatty liver, and belongs to the technical field of biomedicine. The invention provides an application of a fibroblast growth factor 21 in preparation of a medicine for preventing and treating liver injury caused by ischemia-reperfusion or a liver transplanted organ preserving fluid. Hepatic cell injury caused by ischemia-reperfusion can be effectively improved through exogenous supplement of the fibroblast growth factor 21; particularly, aiming at the fatty degeneration transplanted liver, the traditional Chinese medicine composition not only can inhibit color tissue damage, cell apoptosis and inflammation caused by ischemia-reperfusion, but also can improve lipid accumulation in the liver, reverse the fatty degeneration of the liver and improve the fatty degeneration donor liver transplantation curative effect.

Disclosed herein are methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.

To provide a composition for improving liver health.SOLUTION: In one aspect, the composition of the present invention includes a complex component of Gallocatechin Gallate and Isoquercitrin, which effectively reduces oxidative stress and chronic inflammatory reaction that occur during the accumulation of lipids in liver tissue, thereby improving liver health and enabling the prevention, improvement, or treatment of various liver diseases such as hepatitis, cirrhosis, and liver cancer.SELECTED DRAWING: Figure 1

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention discloses a preparation method of an edible flower phenol amide compound and application of the edible flower phenol amide compound in prevention and treatment of non-alcoholic fatty liver disease, and particularly relates to the field of development of new application of food raw materials. The edible flower phenol amide compound N1, N5, N10-coumaroyl spermidine (TCS) can be green extracted by using a natural deep-eutectic solvent (NADES), and can inhibit free fatty acid-induced liver cell lipid accumulation and improve fatty acid-caused liver cell fatty degeneration; oxidative stress and inflammation induced by free fatty acid are inhibited, and expression of senescence-related markers is inhibited, so that development of NAFLD is effectively inhibited.

The invention discloses an application of corilagin in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is proved for the first time that corilagin can reduce lipid accumulation and inhibit oxidative stress through an Nrf2-ARE endogenous antioxidant pathway, has an obvious improvement effect on the non-alcoholic fatty liver disease, and it is proved that corilagin is expected to serve as an alternative medicine for treating the NAFLD, and the corilagin can be used as a medicine for treating the NAFLD. The potential application value is realized on the improvement and treatment of the NAFLD disease.

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

The invention relates to application of a series of compounds in preparation of lipid-lowering drugs. The compounds can reduce lipid accumulation and lipid metabolism related enzyme activity, and can be used for preventing or treating various high-fat related diseases.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The present invention relates to an anti-obesity composition comprising a Geranium wilfordii extract. The extract according to the present invention exhibits an excellent body fat reduction effect by inhibiting lipid accumulation, and thus can be used in pharmaceutical and food fields as an anti-obesity composition.

To provide a novel TGR5 activator comprising a naturally derived component as an active ingredient, and to provide food and beverage or the like for TGR5 activation, enhancement of basal metabolic rate, inhibition of lipid accumulation, as well as anti-obesity, anti-fatigue, or anti-diabetic effects.SOLUTION: This invention has been completed based on the finding that: sedanolide has a TGR5 activating effect.SELECTED DRAWING: Figure 1

The present invention aims to provide a novel pharmaceutical composition that can be used for the treatment or prevention of lysosomal storage diseases, particularly Niemann-Pick disease. [Solution] The present invention provides a pharmaceutical composition for the treatment or prevention of lysosomal storage diseases, characterized by containing a modified γ-cyclodextrin as an active ingredient, wherein the modified γ-cyclodextrin has a monovalent group derived from galacturonic acid that is bonded to a sugar residue of the γ-cyclodextrin via an amide bond.

The invention relates to the technical field of biological fermentation, and discloses sauced rosa roxburghii tratt and a preparation process and application thereof.The sauced rosa roxburghii tratt is prepared through a 1298 fermentation process, namely, the sauced rosa roxburghii tratt is prepared through nine procedures of steam processing, liquid fermentation, separation and juicing, material mixing and yeast stirring under eight fermentation environment parameters in a one-year fermentation period and a liquid-state and solid-state combined fermentation mode, and the sauced rosa roxburghii tratt is obtained. The inherent health attribute of the rosa roxburghii tratt is reserved to the maximum extent, and the sauce flavor is achieved. Efficacy verification tests show that the sauced roxburgh rose can activate phosphorylation expression of adenylate activated protein kinase in a mouse body, reduce fatty acid synthase and inhibit expression of a fat generation gene, so that de novo synthesis of fatty acid is inhibited, lipid accumulation in the liver is reduced, and the effect of preventing and treating liver cancer is achieved. The compound can regulate intestinal flora related to lipid accumulation and energy metabolism, realizes the effect of regulating the non-alcoholic fatty liver, and has a wide application prospect in preparation of large healthy food, health care products and medicines for regulating or improving the non-alcoholic fatty liver.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention provides an application of a rhododendron dauricum extract in treating fatty liver diseases related to metabolic dysfunction. The folium rhododendri daurici extract is obtained by ultrasonic extraction of folium rhododendri daurici powder with an 80% ethanol solution as a solvent and is used for treating a hepatocyte lipid accumulation model and a metabolic dysfunction fatty liver disease mouse model. Experimental results show that the folium rhododendri daurici extract can inhibit lipid accumulation in HepG2 cells, relieve liver lipid accumulation of mice with metabolic dysfunction and fatty liver diseases, reduce TC, TG, AST and ALT levels of serum, reduce MDA expression in the serum, increase GSH expression in liver tissues, relieve liver injury and improve the antioxidant capacity of the mice. Therefore, the folium rhododendri daurici extract has a definite effect in the aspect of treating the metabolic dysfunction fatty liver disease, is simple in extraction process and small in toxic and side effects, and has a wide application prospect.

The invention discloses an application of an epoxidase type II inhibitor, the application is the application in preparation of drugs for treating liver injury, hepatitis, hepatic fibrosis, or liver function decline or complications thereof, and the application discovers that the existing COX-2 selective inhibitors such as celecoxib and the like and a novel efficient COX-2 selective inhibitor 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, the 2, 8-deuterated dimethyl-2-(trifluoromethyl)-2H-benzopyran-3-carboxylic acid disclosed by the invention has the effects of remarkably relieving liver injury, reducing necrosis focus and inflammatory cell infiltration of liver cells and resisting cholestatic hepatic fibrosis; in addition, hepatocyte lipid accumulation and ballooning induced by high fat diet can be reduced, and the progress of lipid hepatitis is remarkably inhibited; it is found for the first time that the traditional Chinese medicine composition can significantly reduce the concentration of serum bilirubin and play a role in relieving hyperbilirubinemia caused by liver injury or liver insufficiency; the traditional Chinese medicine composition can be used for treating neonatal jaundice, congenital bile duct atresia, cholestatic cirrhosis, acute toxic hepatic failure, bilirubin increase caused by acute attack of chronic hepatitis, chronic hepatic failure or hepatic encephalopathy and the like; therefore, the method has obvious economic benefit and clinical application value.

The invention relates to the technical field of biomedicine, in particular to application of an E3 ubiquitin enzyme inhibitor in non-alcoholic fatty liver related drugs. The TRIM23 has obvious influence on the non-alcoholic fatty liver disease, and hepatic cell lipid deposition induced by mixing of palmitic acid and oleic acid can be improved by inhibiting expression of the TRIM23 at the cellular level; on the contrary, promoting the expression level of the TRIM23 can aggravate hepatocyte lipid accumulation induced by mixing of palmitic acid and oleic acid. Therefore, the TRIM23 inhibitor can be used for preparing the medicine for preventing or treating the fatty liver.

The method comprises the following steps: amplifying SIRT3 and SIRT4 genes from human, cloning the SIRT3 and SIRT4 genes to a plasmid vector to construct a pSIRT3-4 plasmid, and mediating the simultaneous expression of the two genes by using an internal ribosome entry site (IRES). According to the present invention, the insulin resistance (IR) model of the HepG2 cell is established by using the 35mM high glucose solution, and after the transfection of the pSIRT3-4 plasmid, the uptake of glucose is improved, the conduction of the insulin signal is recovered, the sensitivity of the HepG2 cell to the insulin is improved, the IR is improved, and the dysfunction of the mitochondria is recovered. The pSIRT3-4 plasmid is wrapped by insulin-coupled cationic liposome and is applied to an IR mouse model, and research proves that lipid accumulation in the IR mouse liver is obviously reduced, and the mitochondrial function of the IR mouse liver is obviously improved. The pSIRT3-4 plasmid constructed by the invention provides a new gene therapy means for the treatment of insulin resistance.